AUS
NZ
UK
CA
USA
IND
Health
Alcidion (ASX:ALC) Lands UK Deal That Turned Heads
May 25, 2026 10:33 AM AEST| By SamAlcidion strengthened its UK healthcare presence with a fresh hospital contract, highlighting growing global demand for digital clinical systems and renewed interest in Australian healthcare technology companies.
Imugene Advances Cancer Research With Azer-cel Progress
May 22, 2026 04:21 PM AEST| By SamImugene strengthens its position in cancer research after releasing encouraging azer-cel clinical trial findings for advanced blood cancer patients in the evolving immunotherapy landscape.
Why ASX Healthcare Stocks Are Back in Focus
May 22, 2026 03:53 PM AEST| By SamASX healthcare shares regain attention as emerging companies advance innovation in kidney disease, cancer care, sleep health, imaging technology and gut health across global markets.
Why Mayne Pharma’s Court Victory Is Turning Heads
May 22, 2026 03:09 PM AEST| By SamMayne Pharma returned to market focus after securing a major court costs order amid growing attention on healthcare regulation and pharmaceutical sector governance.
Why This Healthcare Tech Deal Is Turning Heads
May 22, 2026 12:32 PM AEST| By SamAlcidion attracted renewed market attention after expanding through a Telstra Health deal, highlighting growing momentum across healthcare technology and digital clinical systems.
Why These ASX 200 Shares Are Back In The Spotlight
May 22, 2026 11:16 AM AEST| By SamCSL, Megaport and Treasury Wine Estates are attracting renewed market attention as investors search for ASX recovery opportunities.
Why Oceania Healthcare’s Dividend Pause Is Raising Eyebrows
May 22, 2026 10:06 AM AEST| By SamOceania Healthcare improved earnings, reduced debt and strengthened care margins, but ongoing cash flow pressure continues delaying dividend payments.
IXICO Expands Reach in Neuroscience Research Space
May 21, 2026 07:44 PM AEST| By Vivek SinghIXICO (LSE:IXI) advances its neuroscience imaging capabilities with fresh healthcare research contracts supporting Alzheimer’s and Huntington’s disease development programmes.
Avecho Biotechnology Advances Insomnia Program Momentum
May 21, 2026 04:45 PM AEST| By SamAvecho Biotechnology advances its insomnia treatment program after completing a major clinical trial milestone, strengthening attention on Australia’s evolving cannabidiol healthcare market.
ASX Healthcare Stocks: Why AFT’s Revenue Ambition Is Turning Heads
May 21, 2026 02:21 PM AEST| By SamAFT Pharmaceuticals gained market attention after record earnings and a fresh revenue direction, highlighting healthcare innovation, and expanding international operations within the pharmaceutical sector.
AFT Pharmaceuticals Profit Surges As Global Expansion Gains Momentum
May 21, 2026 01:26 PM AEST| By SamHighlights,AFT Pharmaceuticals reported strong profit growth supported by rising revenue.,Expansion across international healthcare markets continued gaining traction.,Management expects further earnings and sales momentum during the current financia...
Avecho ASX 200 Reports Progress in Insomnia Clinical Trial
May 21, 2026 01:10 PM AEST| By SamAvecho completed the treatment phase for its late-stage insomnia study while advancing interim review procedures linked to pharmaceutical development activities.
CSL’s Canadian HEMGENIX Milestone Could Shift Market Attention Toward Gene Therapy Growth
May 21, 2026 11:18 AM AEST| By SamCSL’s Canadian reimbursement milestone has renewed attention on the company’s gene therapy growth strategy and commercial execution.
Why This ASX Healthcare Stock Is Gaining Fresh Attention
May 21, 2026 10:56 AM AEST| By SamAFT Pharmaceuticals strengthened investor attention after reporting stronger earnings growth and ongoing international healthcare expansion.
AFT Pharma ASX 300 Records Strong FY Twenty Six Profit
May 21, 2026 09:59 AM AEST| By SamAFT Pharmaceuticals recorded a landmark FY twenty six financial outcome with wider international operations, stronger medicine distribution, and expanding healthcare market activity.
Why Is CSL Staying in Focus Across the ASX 200 Market?
May 21, 2026 09:52 AM AEST| By SamCSL remained closely watched across the healthcare sector as biotechnology and pharmaceutical companies continued attracting attention within the ASX market.
Could All Ordinaries TGA Approval Lift OncoSil Focus?
May 20, 2026 06:36 PM AEST| By SamOncoSil strengthened healthcare sector visibility after securing TGA approval for its oncology treatment device as biotechnology innovation and medical technology activity remained central industry themes.
Why These ASX Penny Stocks Are Drawing Fresh Attention
May 20, 2026 04:23 PM AEST| By SamAudinate Group, Alcidion Group, and Austin Engineering are gaining attention as Australian investors focus on financially stable smaller companies operating across technology, healthcare, and mining-linked sectors amid cautious market conditions.
Cracks Beneath the ASX 200 Calm Are Getting Hard to Ignore
May 20, 2026 04:02 PM AEST| By SamAustralian shares may appear stable on the surface, but weakness across retail, healthcare, banking and technology stocks reveals growing pressure from inflation, oil prices and slowing consumer demand.
Could ASX 300 Oncology Progress Lift Nyrada Focus?
May 20, 2026 03:15 PM AEST| By SamNyrada advanced oncology-focused Xolatryp research and US patent activity as biotechnology innovation and pharmaceutical intellectual property discussions strengthened across the healthcare sector.
Advertise your brand on Kalkine Media